Anika Therapeutics, Inc.
Health
Performance
6.1
Risk
Sell
Buy
Curious about the Scores? Learn more.

Anika Therapeutics, Inc. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

11.01.2026
Rock bottom. The fall’s complete, stability nowhere to be found.
26.10.2025
Off life support. Still risky, but slightly less scary.
20.08.2025
Pulse detected. Still fragile, but stabilizing.

Anika Therapeutics, Inc. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Anika Therapeutics, Inc. do? Business model and key facts

Get the full picture of Anika Therapeutics, Inc.: what it builds, where it operates, and how it makes money.

Anika Therapeutics, Inc. Profile

Sector: Healthcare

Industry: Medical - Devices

Employees (FY): 288

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

shop
Company facts
Cheryl Renee Blanchard
CEO
288
Employees worldwide
shop
Performance
-40.51%
Last 12 months
-75.71%
Last 5 years
shop
Growth
$119,91M
Revenue year
$-56.385.000
Net income
shop
Valuation
$134,26M
Market Cap
-4.30
Price/Earnings Ratio

Stocks related to Anika Therapeutics, Inc.

Selected based on industry alignment and relative market positioning.

QIPT
Quipt Home Medical Corp.
3.59
+0.28%
6.4
Sell
Buy
Quipt Home Medical Corp.
TMCI
Treace Medical Concepts, Inc.
2.64
-0.38%
7.8
Sell
Buy
Treace Medical Concepts, Inc.
INGN
Inogen, Inc.
6.25
-3.10%
9.9
Sell
Buy
Inogen, Inc.
ARAY
Accuray Incorporated
0.84
-3.49%
8.9
Sell
Buy
Accuray Incorporated

Anika Therapeutics, Inc. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.